Allergan looks to spend on new programs

"We can afford to pay more than anyone else," FierceBiotech quotes Allergan (AGN +0.5%) CEO David Pyott as saying, in reference to the company's desire to add researchers and make acquisitions in 2014.

AGN "is in a position to spend up to $10B in cash for new deals," John Carroll notes, citing Pyott.

As for 18-month delays in the Darpin and bimatoprost programs, Pyott doesn't understand the concern: "Is it that big a deal? I don't get it."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs